These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38627419)

  • 1. Exposing the molecular heterogeneity of glycosylated biotherapeutics.
    Schachner LF; Mullen C; Phung W; Hinkle JD; Beardsley MI; Bentley T; Day P; Tsai C; Sukumaran S; Baginski T; DiCara D; Agard NJ; Masureel M; Gober J; ElSohly AM; Melani R; Syka JEP; Huguet R; Marty MT; Sandoval W
    Nat Commun; 2024 Apr; 15(1):3259. PubMed ID: 38627419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Equivalence assessment of biotherapeutics with N- and O-glycosylation sites by sequential intact glycoform mass spectrometry (IGMS).
    Oh MJ; Kim U; Kim S; Cho DS; Seo JA; Seo N; An HJ
    J Pharm Biomed Anal; 2023 Sep; 234():115558. PubMed ID: 37393692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relating glycoprotein structural heterogeneity to function - insights from native mass spectrometry.
    Struwe WB; Robinson CV
    Curr Opin Struct Biol; 2019 Oct; 58():241-248. PubMed ID: 31326232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis and characterization of glycan pairing in therapeutic antibodies and Fc-containing biotherapeutics: Addressing current limitations and implications for N-glycan impact.
    Meudt M; Baumeister J; Mizaikoff B; Ebert S; Rosenau F; Blech M; Higel F
    Eur J Pharm Biopharm; 2024 Jul; 200():114325. PubMed ID: 38759899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discrepancies between High-Resolution Native and Glycopeptide-Centric Mass Spectrometric Approaches: A Case Study into the Glycosylation of Erythropoietin Variants.
    Čaval T; Buettner A; Haberger M; Reusch D; Heck AJR
    J Am Soc Mass Spectrom; 2021 Aug; 32(8):2099-2104. PubMed ID: 33856811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Data-independent oxonium ion profiling of multi-glycosylated biotherapeutics.
    Madsen JA; Farutin V; Lin YY; Smith S; Capila I
    MAbs; 2018 Oct; 10(7):968-978. PubMed ID: 30067433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. O-Glycoproteomic analysis of engineered heavily glycosylated fusion proteins using nanoHILIC-MS.
    Cavallero GJ; Wang Y; Nwosu C; Gu S; Meiyappan M; Zaia J
    Anal Bioanal Chem; 2022 Nov; 414(27):7855-7863. PubMed ID: 36136114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry.
    Zhu L; Guo Q; Guo H; Liu T; Zheng Y; Gu P; Chen X; Wang H; Hou S; Guo Y
    MAbs; 2014; 6(6):1474-85. PubMed ID: 25484062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural O-Glycoform Heterogeneity of the SARS-CoV-2 Spike Protein Receptor-Binding Domain Revealed by Top-Down Mass Spectrometry.
    Roberts DS; Mann M; Melby JA; Larson EJ; Zhu Y; Brasier AR; Jin S; Ge Y
    J Am Chem Soc; 2021 Aug; 143(31):12014-12024. PubMed ID: 34328324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteoform-Resolved FcɤRIIIa Binding Assay for Fab Glycosylated Monoclonal Antibodies Achieved by Affinity Chromatography Mass Spectrometry of Fc Moieties.
    Lippold S; Nicolardi S; Wuhrer M; Falck D
    Front Chem; 2019; 7():698. PubMed ID: 31709228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycoproteomics Technologies in Glycobiotechnology.
    Alagesan K; Hoffmann M; Rapp E; Kolarich D
    Adv Biochem Eng Biotechnol; 2021; 175():413-434. PubMed ID: 33205259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simplifying the detection and monitoring of protein glycosylation during in vitro glycoengineering.
    Saunders MJ; Woods RJ; Yang L
    Sci Rep; 2023 Jan; 13(1):567. PubMed ID: 36631484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sweet spot for biologics: recent advances in characterization of biotherapeutic glycoproteins.
    O'Flaherty R; Trbojević-Akmačić I; Greville G; Rudd PM; Lauc G
    Expert Rev Proteomics; 2018 Jan; 15(1):13-29. PubMed ID: 29130774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding glycoprotein structural heterogeneity and interactions: Insights from native mass spectrometry.
    Wu D; Robinson CV
    Curr Opin Struct Biol; 2022 Jun; 74():102351. PubMed ID: 35313141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycosylated Biotherapeutics: Immunological Effects of N-Glycolylneuraminic Acid.
    Yehuda S; Padler-Karavani V
    Front Immunol; 2020; 11():21. PubMed ID: 32038661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human brain glycoform coregulation network and glycan modification alterations in Alzheimer's disease.
    Zhang Q; Ma C; Chin LS; Pan S; Li L
    Sci Adv; 2024 Apr; 10(14):eadk6911. PubMed ID: 38579000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systems analysis of N-glycan processing in mammalian cells.
    Hossler P; Mulukutla BC; Hu WS
    PLoS One; 2007 Aug; 2(8):e713. PubMed ID: 17684559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering the yeast Yarrowia lipolytica for the production of therapeutic proteins homogeneously glycosylated with Man₈GlcNAc₂ and Man₅GlcNAc₂.
    De Pourcq K; Vervecken W; Dewerte I; Valevska A; Van Hecke A; Callewaert N
    Microb Cell Fact; 2012 May; 11():53. PubMed ID: 22548968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Qualitative and quantitative characterization of protein biotherapeutics with liquid chromatography mass spectrometry.
    Qu M; An B; Shen S; Zhang M; Shen X; Duan X; Balthasar JP; Qu J
    Mass Spectrom Rev; 2017 Nov; 36(6):734-754. PubMed ID: 27097288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycosylation of monoclonal antibody products: Current status and future prospects.
    Batra J; Rathore AS
    Biotechnol Prog; 2016 Sep; 32(5):1091-1102. PubMed ID: 27677099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.